BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 7625533)

  • 1. Activity of pentostam (sodium stibogluconate) against cutaneous leishmaniasis in mice treated with neutralizing anti-interferon-gamma antibody.
    Nabors GS; Farrell JP
    Am J Trop Med Hyg; 1995 Jul; 53(1):55-60. PubMed ID: 7625533
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis.
    Scharton-Kersten T; Afonso LC; Wysocka M; Trinchieri G; Scott P
    J Immunol; 1995 May; 154(10):5320-30. PubMed ID: 7730635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of monoclonal anti-IFN-gamma antibodies in vivo abrogates natural resistance of C3H/HeN mice to infection with Leishmania major.
    Belosevic M; Finbloom DS; Van Der Meide PH; Slayter MV; Nacy CA
    J Immunol; 1989 Jul; 143(1):266-74. PubMed ID: 2499629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reconstitution of C.B-17 scid mice with BALB/c T cells initiates a T helper type-1 response and renders them capable of healing Leishmania major infection.
    Varkila K; Chatelain R; Leal LM; Coffman RL
    Eur J Immunol; 1993 Jan; 23(1):262-8. PubMed ID: 8419179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pregnancy impairs resistance of C57BL/6 mice to Leishmania major infection and causes decreased antigen-specific IFN-gamma response and increased production of T helper 2 cytokines.
    Krishnan L; Guilbert LJ; Russell AS; Wegmann TG; Mosmann TR; Belosevic M
    J Immunol; 1996 Jan; 156(2):644-52. PubMed ID: 8543816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice.
    Heinzel FP; Rerko RM; Ahmed F; Pearlman E
    J Immunol; 1995 Jul; 155(2):730-9. PubMed ID: 7608551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leishmania major-infected C3H mice treated with anti-IL-12 mAb develop but do not maintain a Th2 response.
    Hondowicz BD; Scharton-Kersten TM; Jones DE; Scott P
    J Immunol; 1997 Nov; 159(10):5024-31. PubMed ID: 9366430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endogenous interleukin-18 is involved in immunity to Leishmania donovani but its absence does not adversely influence the therapeutic activity of sodium stibogluconate.
    Mullen AB; Lawrence CE; McFarlane E; Wei XQ; Carter KC
    Immunology; 2006 Nov; 119(3):348-54. PubMed ID: 16879623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T helper 1 response against Leishmania major in pregnant C57BL/6 mice increases implantation failure and fetal resorptions. Correlation with increased IFN-gamma and TNF and reduced IL-10 production by placental cells.
    Krishnan L; Guilbert LJ; Wegmann TG; Belosevic M; Mosmann TR
    J Immunol; 1996 Jan; 156(2):653-62. PubMed ID: 8543817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses.
    Nabors GS; Farrell JP
    Infect Immun; 1994 Dec; 62(12):5498-504. PubMed ID: 7960131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A trial of immunotherapy against Leishmania amazonensis infection in vitro and in vivo with Z-100, a polysaccharide obtained from Mycobacterium tuberculosis, alone or combined with meglumine antimoniate.
    Barroso PA; Marco JD; Calvopina M; Kato H; Korenaga M; Hashiguchi Y
    J Antimicrob Chemother; 2007 Jun; 59(6):1123-9. PubMed ID: 17439977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Induction of a Th2 population from a polarized Leishmania-specific Th1 population by in vitro culture with IL-4.
    Mocci S; Coffman RL
    J Immunol; 1995 Apr; 154(8):3779-87. PubMed ID: 7706719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile.
    Skeiky YA; Kennedy M; Kaufman D; Borges MM; Guderian JA; Scholler JK; Ovendale PJ; Picha KS; Morrissey PJ; Grabstein KH; Campos-Neto A; Reed SG
    J Immunol; 1998 Dec; 161(11):6171-9. PubMed ID: 9834103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IFN-gamma produced in vivo during the first two days is critical for resolution of murine Leishmania major infections.
    Leiby DA; Schreiber RD; Nacy CA
    Microb Pathog; 1993 Jun; 14(6):495-500. PubMed ID: 8412622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leishmania donovani: CD2 biased immune response skews the SAG mediated therapy for a predominant Th1 response in experimental infection.
    Bimal S; Sinha S; Singh SK; Narayan S; Kumar V; Verma N; Ranjan A; Sinha PK; Das VN; Pandey K; Kar SK; Das P
    Exp Parasitol; 2012 Jul; 131(3):274-82. PubMed ID: 22580024
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leishmania major: a clone with low virulence for BALB/c mice elicits a Th1 type response and protects against infection with a highly virulent clone.
    Li J; Nolan TJ; Farrell JP
    Exp Parasitol; 1997 Sep; 87(1):47-57. PubMed ID: 9287957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [TH1 response in the experimental infection with Trypanosoma cruzi].
    Cardoni RL; AntĂșnez MI; Abrami AA
    Medicina (B Aires); 1999; 59 Suppl 2():84-90. PubMed ID: 10668248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leishmania donovani vs immunity: T-cells sensitized from Leishmania of one donor may modulate their cytokines pattern on re-stimulation with Leishmania from different donor in visceral leishmaniasis.
    Narayan S; Bimal S; Singh SK; Gupta AK; Singh VP; Sinha PK; Das P
    Exp Parasitol; 2009 Jan; 121(1):69-75. PubMed ID: 18948098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.